Literature DB >> 29785329

Mycosis fungoides in a 15-year-old adolescent.

Sarah Estelmann1, Anna Neuberger1, Ferdinand Toberer1, Christine Fink1, Alexander Enk1, Holger A Haenssle1.   

Abstract

Entities:  

Keywords:  adolescent; childhood; mycosis fungoides

Year:  2018        PMID: 29785329      PMCID: PMC5955079          DOI: 10.5826/dpc.0802a10

Source DB:  PubMed          Journal:  Dermatol Pract Concept        ISSN: 2160-9381


× No keyword cloud information.
Mycosis fungoides (MF), the most frequent primary cutaneous lymphoma, belongs to the group of extranodal non-Hodgkin lymphomas with a mean age at onset of >40 years [1]. The manifestation of MF in children is rare and has only been studied by a number of case series [2]. We report on a 15-year-old female adolescent presenting with pruritic eczematous lesions of the neck and trunk that had persisted for one year (Figure 1A). Clinical examination revealed erythematous, oval-shaped to polycyclic, eczematous macules and plaques with a cigarette paper-like cutaneous atrophy and moderate scaling (Figure 1A–D). The histopathological as well as immunohistochemical investigations included stains for hematoxylin-eosin, CD3, CD4, CD5, CD8, CD20, and CD30, which showed a dense infiltrate of mainly CD3 and CD4 positive atypical lymphocytes with epidermal exocytosis forming Pautrier’s microabscesses (Figure 1E–G). Expression of CD5 as a marker of potential loss of differentiation was retained. Expectedly, flow cytometry analysis of peripheral blood cells showed results within normal limits (36% CD3-positive lymphocytes, CD4:CD8 ratio of 1.5). At the molecular level, a T-cell-receptor (TCR) gene rearrangement analysis from lesional skin showed two monoclonal gene rearrangements, agreeing well with the clinical and histopathological diagnosis of stage IA MF. A topical treatment with 0.1% mometasone furoate cream was initiated and achieved a partial response at the time of the first follow-up examination (6-week interval).
Figure 1

Clinical images and histopathological examination of patches and plaques in a 15-year-old girl with mycosis fungoides. The overview image shows disseminated, bizarrely shaped, erythematous lesions on the back (A). Close-up images reveal more infiltrated erythematous plaques with scaling (B) and patches with epidermal atrophy, sharply demarcated borders and moderate scaling (C, D). Hematoxylin and eosin staining (E) reveals psoriasiform epidermal hyperplasia and a superficial band-like lymphocytic infiltrate. Some of the atypical lymphocytes are present within the epidermis (original magnification × 100). At higher magnification typical Pautrier microabscesses show atypical lymphocytes with hyperchromatic and irregular nuclei (F, original magnification × 630). Immunostaining shows positivity for CD3 marker in epidermotropic, intraepidermal T lymphocytes (G, original magnification × 200). [Copyright: ©2018 Estelmann et al.]

MF is the most common primary cutaneous T-cell lymphoma. However, in children and adolescents MF is very rare with an incidence of 0.05 new cases per year per 100,000 [3]. While in adults the female to male ratio was reported to be 1:2, Nanda et al described a 1:1 ratio in children and adolescents [4]. The difficulties in diagnosing early stage MF in children arise from the multitude of differential diagnoses with similar clinical morphology but much higher incidences in this specific age group. In MF three stages may be differentiated clinically. The patch stage presents with eczematous skin lesions, moderate desquamation, cutaneous atrophy, and predilection for non-sun-exposed skin areas [5]. In children such lesions are often erroneously diagnosed as (atopic) eczema, dermatophyte infection, or early onset psoriasis vulgaris [2]. Therefore, diagnosis is often delayed until the patches evolve into infiltrative plaques (plaque stage) or tumors (tumor stage), with all three types of skin pathologies possibly existing simultaneously [6]. In contrast to most adult cases of MF that show a predominance of CD4-positive pathologic T-cells, many pediatric cases (approximately 50%) are characterized by CD8-positive epidermotropic infiltrates [2]. While a number of relevant molecular mechanisms for the manifestation of MF were reported [5] the exact pathogenesis of MF remains unknown. Many of the affected children are diagnosed at early stages of the disease (stage IA: 50%, stage IB: 47%) [7,8]; however, a mean time interval from first symptoms until a final diagnosis of five years was reported [8]. The prognosis of MF in children and adolescents is more favorable than in adults, with 5-year and 10-year survival rates of 95% and 93%, respectively [3,8]. Skin lesions of the patient presented as erythematous macules and plaques. In contrast, other authors described a high frequency of hypopigmented MF lesions in children often associated with a predominance of CD8-positive atypical T-cells [8] and a non-Caucasian skin phenotype [4]. The literature is somewhat discordant in terms of TCR clonality when assessed in skin biopsies. While Wain et al [8] described monoclonality of TCR genes in 26 of 34 cases (76.5%), Ceppi et al [9] reported of only 3 out of 14 cases (21.4%). There are no specific guidelines for the therapy of juvenile MF. Recommendations for first-line treatment of MF stages IA, IB, and IIA are either emollients plus observation only or, as used in our case, topical corticosteroids. In refractory cases, topical corticosteroids may be combined with phototherapy (broadband/narrowband ultraviolet B [UVB], psoralen and ultraviolet A [PUVA])[1]. Most authors prefer narrowband UVB to broadband UVB or PUVA because of its decreased carcinogenic potential and less side effects [1,10]. As for any phototherapy in children, it should be kept in mind that MF is a chronic disease with slow progression. Repeated phototherapies along the course of the disease may eventually add up to a relevant increase of the risk of UV-induced skin cancers [3].
  9 in total

Review 1.  The pathogenesis of mycosis fungoides.

Authors:  Michael Girardi; Peter W Heald; Lynn D Wilson
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

2.  Brief S2k guidelines--Cutaneous lymphomas.

Authors:  Rudolf Stadler; Chalid Assaf; Claus-Detlev Klemke; Dorothee Nashan; Michael Weichenthal; Reinhard Dummer; Wolfram Sterry
Journal:  J Dtsch Dermatol Ges       Date:  2013-06       Impact factor: 5.584

3.  Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients.

Authors:  Scarlett Boulos; Reena Vaid; Tariq N Aladily; Doina S Ivan; Rakhshandra Talpur; Madeleine Duvic
Journal:  J Am Acad Dermatol       Date:  2014-09-26       Impact factor: 11.527

Review 4.  European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.

Authors:  Franz Trautinger; Johanna Eder; Chalid Assaf; Martine Bagot; Antonio Cozzio; Reinhard Dummer; Robert Gniadecki; Claus-Detlev Klemke; Pablo L Ortiz-Romero; Evangelia Papadavid; Nicola Pimpinelli; Pietro Quaglino; Annamari Ranki; Julia Scarisbrick; Rudolf Stadler; Liisa Väkevä; Maarten H Vermeer; Sean Whittaker; Rein Willemze; Robert Knobler
Journal:  Eur J Cancer       Date:  2017-03-31       Impact factor: 9.162

5.  Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.

Authors:  Weiyun Z Ai; Theresa H Keegan; David J Press; Juan Yang; Laura B Pincus; Youn H Kim; Ellen T Chang
Journal:  JAMA Dermatol       Date:  2014-07       Impact factor: 10.282

Review 6.  Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.

Authors:  Sarah I Jawed; Patricia L Myskowski; Steven Horwitz; Alison Moskowitz; Christiane Querfeld
Journal:  J Am Acad Dermatol       Date:  2014-02       Impact factor: 11.527

7.  Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study.

Authors:  E Mary Wain; Guy E Orchard; Sean J Whittaker; Margaret F Spittle M Sc; Robin Russell-Jones
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

8.  Childhood mycosis fungoides: experience of 28 patients and response to phototherapy.

Authors:  Philip M Laws; Neil H Shear; Elena Pope
Journal:  Pediatr Dermatol       Date:  2014-06-11       Impact factor: 1.588

Review 9.  Primary Cutaneous Lymphomas in Children and Adolescents.

Authors:  Francesco Ceppi; Elena Pope; Bo Ngan; Oussama Abla
Journal:  Pediatr Blood Cancer       Date:  2016-05-27       Impact factor: 3.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.